Detailed Subject Exclusion Criteria for Study Participation
Subjects were not eligible for enrolment if they had any clinically relevant abnormal physical findings which could interfere with the objectives of the trial; a legal incapacity or limited legal capacity; anticipated lack of compliance with study requirements; a history or current evidence of allergy / hypersensitivity ascertained or presumptive to the active drug substance and/or any of the excipients or a history of anaphylaxis to drugs; any clinically significant cardiovascular, renal and hepatic disease or any significant respiratory, endocrine, ophthalmologic, neurologic or psychiatric illness; evidence of respiratory/airway infections or acute other (febrile) infections or illnesses within 2 weeks before enrolment; any surgical or medical condition which could interfere with the absorption, metabolism or excretion of drugs; any history of malignancy within the past 5 years; or any history or evidence of substance abuse or addiction.
Subjects were also excluded if they were current smokers or recent non-smokers for < 3 months prior to enrolment; required or used any prescription or over-the-counter medications within 2 weeks of study initiation, with the exception of paracetamol; reported intake of cytochrome P450 (CYP P450) enzyme inhibitors / inducers within 2 weeks before trial participation; reported excessive consumption of caffeine/xanthine-containing drinks or foods; tested positive for serum HBsAg, anti-HBc, anti-HCV or HIV antibodies (anti-HIV 1 and 2); donated blood within 3 months prior to dosing; planned donation of spermatocytes for medically assisted reproduction techniques within 3 months after treatment of the present study; or participated in clinical trials with investigational medicinal products within 2 months prior to administration of study medication.
Methodological Details of Safety Assessments

Spirometry
Pulmonary function was examined on treatment days after subjects had been rested at least 5 min in sitting position at predose, and at 15, 45 min, and 1.25, 2.5, 3.5, 6, and 24 h postdose (i.e. t 0 ) using a calibrated spirometer (Vitalograph Compact, Vitalograph GmbH, Germany). Testing was performed in compliance with the ATS/ERS standards. 18 Subjects were instructed to exercise a maximal forced expiration over at least 6 sec, and at least 3 measurements were made. Captured variables included vital capacity (VC; L); forced vital capacity (FVC; L); forced expiratory volume in the first second (FEV 1 ; in L); FEV 1 expressed as percentage of VC (FEV 1 %); peak expiratory flow rate (PEF; L/sec); maximum expiratory flow rates at 25/50/75 % of the FVC (MEF25/50/75 %; in L/sec). FEV 1 and FVC were considered and analysed as the primary safety parameters of interest. The values recorded for FEV 1 and FVC were the highest values obtained from three acceptable curves.
Exhaled Nitric Oxide
Exhaled nitric oxide (eNO) was quantified as a marker of airway inflammation on treatment days using a calibrated Niox ® Mino device (Habel Medizintechnik, Austria), in compliance with ATS/ERS recommendations. 18 Testing was performed immediately prior to each lung function assessment, with the exception of the 15 min post-dose timepoint.
Vital Signs
Systolic and diastolic blood pressure (SBP/DBP) and pulse rate (PR) were measured on treatment days by using an oscillometric device (HP monitor 66S, Hewlett P Packard, USA) at predose, and 0.5, 1, 2, 4 and 12 h post-dose. Oral body temperature was captured predose and 24 h post-dose.
Electrocardiogram
Standard 12-Leads ECGs (Siemens Megacard, Siemens, Germany) were recorded on treatment days after subjects had rested at least 5 min in supine position using the leads according to Einthoven and Goldberger as well as 6 precordial leads according to Wilson, at predose 30 min, 1, 2, 4, 12, and 24 h post-dose. Safety variables of primary interest were HR, and time intervals for PQ (=PR), QRS, QT, QTc, and RR, as well as possible changes of T-wave morphology. The heart rate corrected QT interval (QTc) was calculated according to the square root formula of Bazett, and analyzed according to recommendations provided by the ICH E14 guideline. 19
Safety Laboratory
Blood samples for standard safety laboratory assessments (i.e. haematology incl. differential white blood cell (WBC) counts, clinical chemistry, coagulation parameters and urinalysis) were taken with subjects in supine position and fasted state on treatment days, predose and 24 h post-dose, and analysed in the Central Laboratory of the Medical University of Vienna.
Adverse Events
Subjects' well-being in terms of nature, severity, assumed causal relationship to treatment, and frequency of treatment emergent adverse events (TEAEs) was documented throughout the study, i.e. from subject enrolment until the end-of-study examination.
Methodological Details of Plasma and Urine Sample Processing
For the determination of plasma concentrations of AP301 blood samples were collected in closed vacuum tubes (Lithium Heparin Vacuette System, Greiner Bio-One, Austria).
Immediately after blood draw the tubes were placed on ice for ≤ 30 min, and thereafter centrifuged at 4°C for 10 min at 2,500 g to obtain plasma. The resulting supernatant of the samples was transferred into polypropylene plastic tubes (divided in two aliquots) and frozen within 60 min after blood sampling in upright position in dry ice. Samples were stored in a freezer under continuous temperature control between -20°C to -30°C until analysis.
Urine was collected after subjects had emptied their bladder prior to AP301 administration over a 4 h interval post-dose. Throughout the sampling period urine containers were kept refrigerated at approximately 4°C. At the end of each collection interval urine volume was quantified and after thorough mixing, two aliquots of 10 mL each were stored in polypropylene tubes at -20°C until analysis.
Methodological Details of Pharmacokinetic Analyses
Drug concentration-time data for each subject were analyzed by standard noncompartmental pharmacokinetic methods. PK parameters were calculated using validated software (WinNonLin ® 5.2, Pharsight Corporation, USA). The analysis of all pharmacokinetic (PK) variables was performed on the per protocol (PP) population, which comprised all randomised subjects without major protocol deviations with potential relevance for the PK analyses.
The following PK variables were directly taken from the data or calculated according to standard procedures and algorithms: maximum observed plasma concentration (C max ); time to maximum observed plasma concentration (t max ); total exposure (area under the plasma concentration -time curve from time zero to time of last quantifiable measurable concentration (AUC 0-t ). Because of the very low and transient AP301 plasma exposure levels, other standard PK variables such as the terminal rate constant ( z ), and dependent variables (i.e. AUC 0-t extrapolated to infinity (AUC 0-∞ ); terminal plasma disposition half-life (t 1/2 )) were not calculated. Also, application of any dose-normalisation to C max and AUC data did not appear meaningful. Due to the limited systemic AP301 exposure observed across treatments no statistical analyses were applied on PK data. Table S1 : FVC (L) assessed before and after inhalation of AP301 or matching placebo for each dose level and overall. Arithmetic means ± SD and medians (ranges) are displayed. Online Supplement Figure S2 :
Online Supplement
Arithmetic mean baseline and post-dose PQ-and QTc-intervals of the ECG by AP301 dose-group (N=6) and pooled placebo recipients (N=12). 
